Literature DB >> 32796319

Differential actions of indomethacin: clinical relevance in headache.

Oliver Summ1, Anna P Andreou1, Simon Akerman1, Philip R Holland2, Jan Hoffmann2, Peter J Goadsby1,2.   

Abstract

ABSTRACT: Nonsteroidal anti-inflammatory drugs, cyclooxygenase inhibitors, are used routinely in the treatment of primary headache disorders. Indomethacin is unique in its use in the diagnosis and treatment of hemicrania continua and paroxysmal hemicrania. The mechanism of this specific action is not fully understood, although an interaction with nitric oxide (NO) signaling pathways has been suggested. Trigeminovascular neurons were activated by dural electrical stimulation, systemic administration of an NO donor, or local microiontophoresis of L-glutamate. Using electrophysiological techniques, we subsequently recorded the activation of trigeminovascular neurons and their responses to intravenous indomethacin, naproxen, and ibuprofen. Administration of indomethacin (5 mg·kg-1), ibuprofen (30 mg·kg-1), or naproxen (30 mg·kg-1) inhibited dural-evoked firing within the trigeminocervical complex with different temporal profiles. Similarly, both indomethacin and naproxen inhibited L-glutamate-evoked cell firing suggesting a common action. By contrast, only indomethacin was able to inhibit NO-induced firing. The differences in profile of effect of indomethacin may be fundamental to its ability to treat paroxysmal hemicrania and hemicrania continua. The data implicate NO-related signaling as a potential therapeutic approach to these disorders.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32796319      PMCID: PMC7808353          DOI: 10.1097/j.pain.0000000000002032

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  65 in total

1.  Rizatriptan has central antinociceptive effects against durally evoked responses.

Authors:  M J Cumberbatch; R G Hill; R J Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-06-05       Impact factor: 4.432

2.  Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen.

Authors:  Wei Fan; Yong Wu; Xian-Kun Li; Nian Yao; Xun Li; Yong-Guo Yu; Li Hai
Journal:  Eur J Med Chem       Date:  2011-05-20       Impact factor: 6.514

Review 3.  Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.

Authors:  J A Mitchell; T D Warner
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

Review 5.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

6.  Nitric oxide production by Leishmania-infected macrophages and modulation by prostaglandin E2.

Authors:  M A Panaro; O Brandonisio; M Sisto; A Acquafredda; D Leogrande; L Fumarola; V Mitolo
Journal:  Clin Exp Med       Date:  2001-09       Impact factor: 3.984

7.  Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus.

Authors:  S Koulchitsky; M J M Fischer; K Messlinger
Journal:  Cephalalgia       Date:  2008-11-25       Impact factor: 6.292

8.  Putative antinociceptive action of nitric oxide in the caudal part of the spinal trigeminal nucleus during chronic carrageenan-induced arthritis in the rat temporomandibular joint.

Authors:  Silvia A Tesser-Viscaíno; Alexandre Denadai-Souza; Simone A Teixeira; Edílson Ervolino; Roelf J Cruz-Rizzolo; Soraia K Costa; Marcelo N Muscará; Cláudio A Casatti
Journal:  Brain Res       Date:  2009-09-19       Impact factor: 3.252

9.  Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia.

Authors:  Mirjam Eberhardt; Lars Neeb; Eva-Maria Vogel; Gisa Tiegs; Uwe Reuter; Karl Messlinger; Michael J M Fischer
Journal:  Neuropeptides       Date:  2009-10-27       Impact factor: 3.286

10.  Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide.

Authors:  H K Iversen; J Olesen
Journal:  Cephalalgia       Date:  1994-12       Impact factor: 6.292

View more
  4 in total

1.  Indomethacin for refractory COVID or post-COVID headache: a retrospective study.

Authors:  Abouch V Krymchantowski; Raimundo Pereira Silva-Néto; Carla Jevoux; Ana Gabriela Krymchantowski
Journal:  Acta Neurol Belg       Date:  2021-09-21       Impact factor: 2.471

2.  Prominent Indomethacin-Induced Enteropathy in Fcgriib Defi-cient lupus Mice: An Impact of Macrophage Responses and Immune Deposition in Gut.

Authors:  Thansita Bhunyakarnjanarat; Kanyarat Udompornpitak; Wilasinee Saisorn; Bhumdhanin Chantraprapawat; Peerapat Visitchanakun; Cong Phi Dang; Jiraphorn Issara-Amphorn; Asada Leelahavanichkul
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

3.  Long-Term Outcome of Indomethacin Treatment in Pediatric Patients with Paroxysmal Hemicrania-A Case Series.

Authors:  Maximilian David Mauritz; Anna Enninger; Christine Wamsler; Julia Wager; Boris Zernikow
Journal:  Children (Basel)       Date:  2021-02-03

4.  Indomethacin has no effect on trigeminally provoked parasympathetic output.

Authors:  Maike Möller; Celina Schröder; Stefanie Iwersen-Bergmann; Jan Mehnert; Arne May
Journal:  Cephalalgia       Date:  2021-08-18       Impact factor: 6.292

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.